Published in final edited form as:

Angew Chem Int Ed Engl. 2016 August 16; 55(34): 9894–9897. doi:10.1002/anie.201603488.

Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation**

Nick Cox^[b], James R. Kintzing^[a], Mark Smith^[b], Gerald A. Grant^[c], and Jennifer R. Cochran^[a]

^[a]Department of Bioengineering, Stanford University, Stanford, CA 94305, United States, Jennifer.Cochran@stanford.edu

^[b]Stanford ChEM-H Medicinal Chemistry Knowledge Center, Stanford University, Stanford, CA 94305, United States

^[c]Department of Neurosurgery, Stanford University, Stanford, CA 94305, United States

Abstract

Antibody-drug conjugates (ADCs) offer increased efficacy and reduced toxicity compared to systemic chemotherapy. Less attention has been paid to peptide-drug delivery, which has the potential for increased tumor penetration and facile synthesis. We report a knottin peptide-drug conjugate (KDC) and demonstrate that it can selectively deliver gemcitabine to malignant cells expressing tumor-associated integrins. This KDC binds to tumor cells with low-nanomolar affinity, is internalized by an integrin-mediated process, releases its payload intracellularly, and is a highly potent inhibitor of brain, breast, ovarian, and pancreatic cancer cell lines. Notably, these features enable this KDC to bypass a gemcitabine resistance mechanism found in pancreatic cancer cells. This work expands the therapeutic relevance of knottin peptides to include targeted drug delivery, and further motivates efforts to expand the drug-conjugate toolkit to include non-antibody protein scaffolds.

Keywords

knottins; peptides; drug delivery; integrins; antitumor agents

Cystine-knot mini-proteins or “knottins” are short (30–50 amino acid) peptides^[1] that possess many therapeutically desirable characteristics.^[2] These include high thermal and proteolytic stability and the potential for oral administration;^[3] features resulting from a highly compact cystine knot framework. As a result, several knottins have been investigated for clinical applications^[4] including treatments for cancer,^[5] chronic pain,^[6] wasting syndrome,^[7] and as tumor-imaging agents.^[8]

[**] This work was supported by the National Institutes of Health (1K08NS075144–01), the Stanford Child Health Research Institute, Stanford BioX-IIP Program, Stanford ChEM-H, and an NSF Graduate Research Fellowship (to J.R.K.). Supporting information for this article is given on the WWW under <http://dx.doi.org/10.1002/anie.201603488>.

Correspondence to: Jennifer R. Cochran.

N.C., J.R.K., M.S., and J.R.C. are inventors of Stanford-owned intellectual property related to this technology. G.A.G. declares no competing financial interests.

We have developed an engineered knottin, EETI-2.5F (**1**), which has been evolved to target a panel of integrin receptors (including $\alpha v\beta 3$, $\alpha v\beta 5$, and $\alpha 5\beta 1$) that are highly-expressed in many types of cancer.^[9] Due to the role of integrins in cellular proliferation, migration, angiogenesis,^[10] and adhesion to the extracellular matrix,^[11] elevated integrin expression plays a critical role in tumor progression.^[12] As a result, integrins have received significant attention as potential targets in cancer intervention.^[12–13]

Previously, we showed that when labeled with fluorescent small molecules,^[14] radioisotopes,^[14–15] or ultrasound contrast reagents,^[16] **1** can be used for the *in vivo* imaging of tumors in mice, including intracranial patient derived xenografts^[8b, 8c] (Fig 1A). These studies showed high tumor imaging contrast with low levels of probe accumulation in non-target organs. We reasoned that **1** might be leveraged to deliver a drug payload selectively to tumors; a highly desirable goal as evidenced by significant investment in the development of ADCs over the past 60 years.^[17]

In this work (Fig. 1B) we describe a series of knottin peptide-drug conjugates, synthesized using a variety of drug-linker strategies, and highlight an optimal conjugate as a potent inhibitor of tumor cell growth *in vitro* against a variety of malignant cell lines. We also provide evidence that: 1) integrin-binding is essential for potency, 2) the mechanism of internalization is integrin-mediated, and 3) the drug payload is released intracellularly. As shown in Figure 2, we envisioned that a variant of knottin EETI-2.5F (**1**) containing an azide-bearing unnatural amino acid would allow for efficient preparation of drug conjugates via azide-alkyne cycloaddition. In support of this strategy, we recently described a version of EETI-2.5F which tolerated the substitution of an unnatural amino acid at position 15.^[18] We therefore prepared the azido-variant EETI-2.5Z (**2**) via solid-phase peptide synthesis and showed that it retained low-nanomolar binding affinity to U87MG glioblastoma cells (Fig. 2).

We next sought a cytotoxic payload that could be efficiently conjugated to **2**. We identified gemcitabine (**3**)^[19] as a candidate given its precedence as a widely-used chemotherapeutic,^[20] its high potency against malignant cells,^[21] and its tractable derivatization from inexpensive starting materials. We anticipated that linker stability would be a critical design consideration; ideally the linker will remain stable in the extracellular environment and release its payload only upon internalization. We therefore prepared alkyne-bearing gemcitabine derivatives tethered via several functional groups including an ester (**4a**), a carbamate (**4b**), and an amide (**4c**). Additionally, given the extensive use of dipeptide-based cleavable linkers in ADCs,^[17c] we prepared the Val-Ala-PAB (valyl-alanyl-para-aminobenzyloxy) derivative (**4d**) which employs a linker known to be stable extracellularly but which is cleaved upon internalization by proteases such as cathepsin B.^[22] Each gemcitabine derivative was then linked to EETI-2.5Z via copper-catalyzed azide-alkyne cycloaddition^[23] (Scheme 1B) to afford KDCs (**5a-d**).

Once the KDCs **5a-d** were prepared, we measured their binding affinity to U87MG glioblastoma cells, which have elevated expression of tumor-associated integrins.^[24] As shown in Table 1, all KDCs tested bound to U87MG cells with low-nanomolar affinity, indicating that the presence of the linker and drug do not interfere with tumor targeting by

the knottin. Next, we tested the potency of each KDC in a cell-proliferation experiment. We found that KDCs with linkers containing the ester (**5a**), amide (**5c**), and Val-Ala-PAB (**5d**) moieties demonstrated low-nanomolar ED₅₀ values in U87MG cells, similar to unconjugated gemcitabine (**3**). In contrast, EETI-2.5Z (**2**) was not potent, indicating that the conjugation of **3** is necessary for growth inhibition. The KDC containing the carbamate linker (**5b**) also lacked significant potency, which can be explained by the greater stability of its linker^[25] and the requirement of linker cleavage in order for the payload to become active.^[26]

We next sought to determine the relative extent of premature drug-release in order to identify the linker best-suited for delivering the drug payload intracellularly. We employed an established technique for blocking the cellular uptake of gemcitabine using *S*-(4-nitrobenzyl)-6-thioinosine (**6**), which inhibits nucleoside transporters, such as the human Equilibrative Nucleoside Transporter 1 (hENT1).^[27] Because hENT1 is a critical regulator of the cellular internalization of **3**,^[28] by inhibiting its activity with **6**, the cytotoxic effect of any drug released extracellularly would be diminished. We anticipated that this would allow us to differentiate KDCs that were potent due to the undesirable release of **3** outside of the cell (see Scheme S10 in Supporting Information). As shown in Figure 3, the ED₅₀ values of unconjugated **3** as well as KDC **5a** in U87MG cells increased significantly when cells were treated with increasing concentrations of **6**. These results indicate that in the case of **5a**, a significant amount of the linker is cleaved prematurely outside of the cell, and that the released payload **3** is still reliant upon hENT1 activity for cellular uptake. However, in the case of **5c** and **5d**, we found that potency was much less sensitive to the concentration of **6**. In particular, treatment with **6** appeared to have no effect on the potency of EETI-2.5Z-Val-Ala-PAB-gemcitabine (**5d**), and exhibited only minimal effects when the highest dose of **6** (10 μM) was used. This suggests that the mechanism of internalization of the drug payload in the case of **5d** is independent of hENT1, indicative of minimal premature drug release.

In order to determine the importance of integrin-binding for the potency of each KDC, we carried out a competition experiment in which U87MG cells were pre-treated with unconjugated EETI-2.5F (**1**), thereby blocking integrins on the cell surface. In agreement with the hENT1 inhibition experiment, we found that pre-treatment with **1** did not diminish the potency of **5a** and **5c** (see Figs. S11–12 in Supporting Information). This suggests that for these KDCs, integrin binding is not essential for internalization of the payload, consistent with a case where potency results primarily from premature drug release. In stark contrast, we found that pre-treatment of U87MG cells with **1** abolishes the potency of KDC **5d**, even at the highest concentration tested (Fig. 4). This suggests that for **5d**, integrin-binding is a critical part of the mechanism by which it delivers its cytotoxic payload, consistent with integrin-mediated internalization followed by intracellular drug-release. Taken together, the results shown in Table 1 and Figures 3 and 4 suggest that KDC **5d**: 1) targets cells based on the expression of tumor-associated integrins, 2) is internalized via a mechanism that relies upon integrin-binding, and 3) releases its drug payload in significant amounts only upon intracellular degradation of the linker, likely by lysosomal proteases such as cathepsin B.^[22]

Having identified KDC **5d** as a potent inhibitor of U87MG cells with desirable payload release properties, we next tested its efficacy against a variety of other cell lines in comparison with gemcitabine (**3**). As shown in Table 2 (entries 2–5), **5d** is also a highly

potent inhibitor of D270 glioblastoma, MDA-MB-468 breast cancer, A2780 ovarian cancer, and BxPC3 pancreatic cancer cell lines. The high potency of **5d** against PANC-1 pancreatic cancer cells (Table 2 entry 6) is particularly noteworthy given the high resistance of this cell line to gemcitabine, which is thought to be associated with its diminished nucleoside transporter activity.^[29] Our data suggests that the significantly higher potency of **5d** against this cell line results from an alternative, integrin-mediated pathway for cellular uptake, obviating reliance on transporters such as hENT1.

In conclusion, we describe an engineered knottin peptide-drug conjugate, EETI-2.5Z-Val-Ala-PAB-gemcitabine (**5d**) and show that it is a highly potent inhibitor of tumor growth in a broad panel of malignant cell lines. Our results show that this KDC targets malignant cells by binding selectively to tumor-associated integrins, and that release of its cytotoxic payload is governed by intracellular processes. Overall, these results motivate further development and testing of KDCs for applications in cancer therapy. In addition, this work supports strategies relying upon tumor-associated integrins as targets for drug delivery, and validates antibody-alternatives as scaffolds for drug conjugation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are grateful for NMR and MS support provided by the Stanford Magnetic Resonance Laboratory (SMRL) and Stanford University Mass Spectrometry (SUMS), respectively. We are also grateful to Dr. Toni Kline of Sutro Biopharma, Inc. for helpful discussions.

References

- [1]. a)Le Nguyen D, Heitz A, Chiche L, Castro B, Boigegrain RA, Favel A, Coletti-Previero MA, Biochimie 1990, 72, 431–435; [PubMed: 2124146] b)Pallaghy PK, Norton RS, Nielsen KJ, Craik DJ, Protein Science 1994, 3, 1833–1839. [PubMed: 7849598]
- [2]. Kolmar H, Curr. Opin. Pharmacol 2009, 9, 608–614. [PubMed: 19523876]
- [3]. a)Werle M, Schmitz T, Huang H-L, Wentzel A, Kolmar H, Bernkop-Schnürch A, Drug Target J. 2006, 14, 137–146;b)Kolmar H, FEBS Journal 2008, 275, 2684–2690. [PubMed: 18435757]
- [4]. Moore SJ, Leung CL, Cochran JR, Drug Discov. Today Technol. 2012, 9, e3–e11.
- [5]. a)Graf N, Mokhtari TE, Papayannopoulos IA, Lippard SJ, J. Inorg. Biochem 2012, 110, 58–63; [PubMed: 22465700] b)Dardevet L, Rani D, Aziz TA, Bazin I, Sabatier JM, Fadl M, Brambilla E, De Waard M, Toxins 2015, 7, 1079–1101. [PubMed: 25826056]
- [6]. Williams JA, Day M, Heavner JE, Expert Opin. Pharmacother 2008, 9, 1575–1583. [PubMed: 18518786]
- [7]. Joppa MA, Gogas KR, Foster AC, Markison S, Peptides 2007, 28, 636–642. [PubMed: 17204351]
- [8]a). Veisheh M, Gabikian P, Bahrami S-B, Veisheh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM, Cancer Res. 2007, 67, 6882–6888; [PubMed: 17638899] b)Moore SJ, Hayden Gephart MG, Bergen JM, Su YS, Rayburn H, Scott MP, Cochran JR, Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 14598–14603; [PubMed: 23950221] c)Ackerman SE, Wilson CM, Kahn SA, Kintzing JR, Jindal DA Grant G, Cochran J, Cureus 2014, 6.
- [9]. a)Kimura RH, Levin AM, Cochran FV, Cochran JR, Proteins: Struct., Funct., Bioinf. 2009, 77, 359–369;b)Silverman AP, Levin AM, Lahti JL, Cochran JR, J. Mol. Biol 2009, 385, 1064–1075. [PubMed: 19038268]

- [10]. Brooks P, Clark R, Cheresch D, Science 1994, 264, 569–571. [PubMed: 7512751]
- [11]. Hynes RO, Cell 1992, 69, 11–25. [PubMed: 1555235]
- [12]. Desgrosellier JS, Cheresch DA, Nat. Rev. Cancer 2010, 10, 9–22. [PubMed: 20029421]
- [13]. a)Cox D, Brennan M, Moran N, Nat. Rev. Drug Discovery 2010, 9, 804–820; [PubMed: 20885411] b)Goodman SL, Picard M, Trends Pharmacol. Sci 2012, 33, 405–412. [PubMed: 22633092]
- [14]. Kimura RH, Cheng Z, Gambhir SS, Cochran JR, Cancer Res. 2009, 69, 2435–2442. [PubMed: 19276378]
- [15]. a)Nielsen CH, Kimura RH, Withofs N, Tran PT, Miao Z, Cochran JR, Cheng Z, Felsher D, Kjaer A, Willmann JK, Gambhir SS, Cancer Res. 2010, 70, 9022–9030; [PubMed: 21062977] b)Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR, Bioconjugate Chem. 2010, 21, 436–444.
- [16]. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS, J. Nucl. Med 2010, 51, 433–440. [PubMed: 20150258]
- [17]a). Schrama D, Reisfeld RA, Becker JC, Nat. Rev. Drug Discovery 2006, 5, 147–159; [PubMed: 16424916] b)Sievers EL, Senter PD, Annu. Rev. Med 2013, 64, 15–29; [PubMed: 23043493] c)Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, Borzilleri RM, Drug Discov. Today 2014, 19, 869–881. [PubMed: 24239727]
- [18]. Kim JW, Cochran FV, Cochran JR, J. Am. Chem. Soc 2015, 137, 6–9. [PubMed: 25486381]
- [19]. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W, Cancer Res. 1991, 51, 6110–6117. [PubMed: 1718594]
- [20]. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F, Future Oncology 2005, 1, 7–17. [PubMed: 16555971]
- [21]. a)Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB, Cancer Res. 1990, 50, 4417–4422; [PubMed: 2364394] b)Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, Tanzer LR, Boder GB, Grindey GB, Investigational New Drugs, 14, 243–247. [PubMed: 8958178]
- [22]. a)Burke PJ, Toki BE, Meyer DW, Miyamoto JB, Kissler KM, Anderson M, Senter PD, Jeffrey SC, Bioorg. Med. Chem. Lett 2009, 19, 2650–2653; [PubMed: 19386499] b)Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law C-L, Senter PD, Bioconjugate Chem. 2013, 24, 1256–1263.
- [23]. Meldal M, Tornøe CW, Chem. Rev 2008, 108, 2952–3015. [PubMed: 18698735]
- [24]. Bello L, Francolini M, Marthyn P, Zhang J, Carroll RS, Nikas DC, Strasser JF, Villani R, Cheresch DA, Black PM, Neurosurgery 2001, 49, 380–390. [PubMed: 11504114]
- [25]. Huang TL, Szekacs A, Uematsu T, Kuwano E, Parkinson A, Hammock BD, Pharm. Res 1993, 10, 639–648. [PubMed: 8321828]
- [26]. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T, Ann. Oncol 2006, 17 Suppl 5, v7–12. [PubMed: 16807468]
- [27]. a)Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD, J. Biol. Chem 2011, 286, 32552–32562; [PubMed: 21795683] b)Sundaram M, Yao SY, Ingram JC, Berry ZA, Abidi F, Cass CE, Baldwin SA, Young JD, J. Biol. Chem 2001, 276, 45270–45275. [PubMed: 11584005]
- [28]. a)Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE, Oncogene 2003, 22, 7524–7536; [PubMed: 14576856] b)Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE, Cancer Metastasis Rev. 2007, 26, 85–110. [PubMed: 17345146]
- [29]. a)Tsujiie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, Nagano H, Dono K, Umeshita K, Sakon M, Monden M, Anticancer Res. 2007, 27, 2241–2249; [PubMed: 17695509] b)Mori R, Ishikawa T, Ichikawa Y, Taniguchi K, Matsuyama R, Ueda M, Fujii Y, Endo I, Togo S, Danenberg PV, Shimada H, Oncol. Rep 2007, 17, 1201–1205. [PubMed: 17390066]

A: Previous Work:

knottins for tumor imaging

B: This Work:

knottins for tumor-targeted drug delivery

Figure 1.

A: Previous work: knottins labelled with fluorescent small molecules, radioisotopes, and ultrasound contrast reagents for tumor-imaging. B: This work: knottin peptide-drug conjugates (KDCs) for tumor-targeted drug delivery.

Figure 2.

Sequence of EETI 2.5F (1) and EETI 2.5Z (2) with integrin-binding loop highlighted in blue and disulfide linkages of the cystine-knot scaffold depicted in yellow. Position 15 (red X) indicates the site where an azide-containing unnatural amino acid, 5-azido-L-norvaline, was installed to allow for site-specific bioconjugation of linker-drug constructs. Substitution at this position does not disrupt binding to U87MG cells.

Figure 3.

KDC **5d** demonstrates minimal extracellular drug-release. Blocking U87MG cellular uptake of gemcitabine **3** (black) with hENT1 inhibitor **6** significantly diminishes its potency. This effect is also observed with KDCs **5a** (gray), and **5c** (dashed), indicating significant extracellular drug-release. Meanwhile, the ED₅₀ of **5d** (red) is insensitive to **6**, indicating little premature drug-release.

Figure 4.

Integrin-binding is essential for the potency of KDC **5d**. Blocking integrins on the surface of U87MG cells by competition with 1 μ M of un-labelled knottin **1** significantly reduces the potency of KDC **5d** (red), indicating that integrin-binding is critical for inhibition of tumor cell growth. Meanwhile, integrin blocking by **1** does not diminish the potency of gemcitabine **3** (black).

Scheme 1.

A: Synthesis of alkyne-bearing gemcitabine derivatives **4a-d** containing cleavable linkers. Bonds highlighted in red indicate likely sites for drug cleavage to release gemcitabine. B: Conjugation of compounds **4a-d** to EETI-2.5Z via Cu-catalyzed azide-alkyne cycloaddition, affording KDCs **5a-d**.

Table 1.Binding affinity (IC₅₀) and potency (ED₅₀) in U87MG cells.

	Compound	Description	IC ₅₀ (nM) ^[a]	ED ₅₀ (nM) ^[b]
1	2	<i>EETI-2,5Z w/o drug</i>	1.1 ± 1.8	> 1,000
2	5a	<i>ester linker</i>	5.2 ± 3.6	8.5 ± 3.3
3	5b	<i>carbamate linker</i>	3.3 ± 0.2	> 1,000
4	5c	<i>amide linker</i>	2.8 ± 0.2	8.9 ± 1.2
5	5d	<i>Val-Ala-PAB linker</i>	1.5 ± 0.2	9.0 ± 1.8
6	3	<i>gemcitabine</i>	N/A	1.1 ± 1.4

^[a] Cells bound w/ AF488-labeled **1** were titrated with each compound and percent bound was measured by flow cytometry.

^[b] Cell proliferation was quantified 4 d after treatment with each compound using CCK-8 colorimetric assays and compared to untreated control.

Table 2.Cell growth inhibition by KDC (5d) vs. gemcitabine (3).^[a]

	Cell Line	Cancer Type	5d ED ₅₀ (nM)	3 ED ₅₀ (nM)
1	U87MG	<i>glioblastoma</i>	9.0 ± 1.8	1.7 ± 1.4
2	D270	<i>glioblastoma</i>	7.9 ± 0.8	1.5 ± 0.4
3	MB-468	<i>breast</i>	0.6 ± 0.1	10.3 ± 6.8
4	A2780	<i>ovarian</i>	2.3 ± 0.5	0.5 ± 0.02
5	BxPC3	<i>pancreatic</i>	1.8 ± 0.8	18.4 ± 1.3
6	PANC-1	<i>pancreatic</i>	2.1 ± 0.2	52.8 ± 4.9

^[a] Cell proliferation was quantified 4 d after treatment with **5d** or **3** using CCK-8 colorimetric assays and compared to untreated control.